Last updated on April 2016

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)


Brief description of study

This phase 2b, 8-week, randomized, double-blind, parallel group, multi-center study with a 4-week, placebo-controlled, randomized withdrawal period will evaluate the efficacy, safety and tolerability of Tenapanor to treat hyperphosphatemia in end-stage renal disease patients on hemodialysis (ESRD-HD). Subjects who qualify are randomized into the study will either receive 3 mg BID, 10 mg BID, or a titration regimen of tenapanor.

Detailed Study Description

The study consists of a screening visit, a wash out period of up to 3 weeks, when existing phosphate lowering medication is withheld, an 8-week treatment period, in which all groups receive tenapanor, and a 4-week placebo-controlled, randomized withdrawal period, during which patients are re-randomized 1:1 to either remain on their current tenapanor treatment or placebo. Depending on the increase in serum phosphate levels, subjects can be randomized 1,2, or 3 weeks after being taken off their phosphate lowering medication.

Clinical Study Identifier: NCT02675998

Find a site near you

Start Over

Ardelyx Investigative Site 429

Huntsville, AL United States
  Connect »

Ardelyx Investigative Site 425

Riverside, CA United States
  Connect »

Ardelyx Clinical Site 403

Denver, CO United States
  Connect »

Ardelyx Investigative Site 410

Lauderdale Lakes, FL United States
  Connect »

Ardelyx Investigative Site 432

Shreveport, LA United States
  Connect »

Ardelyx Investigative Site 402

Kalamazoo, MI United States
  Connect »

Ardelyx Investigative Site 424

Roseville, MI United States
  Connect »

Ardelyx Investigative Site 409

Brookhaven, MS United States
  Connect »

Ardelyx Investigative Site 423

St. Louis, MO United States
  Connect »

Ardelyx Investigative Site 416

Albuquerque, NM United States
  Connect »

Ardelyx Investigative Site 408

Asheville, NC United States
  Connect »

Ardelyx Investigative Site 411

Charlotte, NC United States
  Connect »

Ardelyx Investigative Site 412

Wilmington, NC United States
  Connect »

Ardelyx Investigative Site 414

Bethlehem, PA United States
  Connect »

Ardelyx Investigative Site 421

Orangeburg, SC United States
  Connect »

Ardelyx Investigative Site 413

Knoxville, TN United States
  Connect »

Ardelyx Investigative Site 418

Nashville, TN United States
  Connect »

Ardelyx Investigative Site 405

Bellville, TX United States
  Connect »

Ardelyx Investigative Site 422

San Antonio, TX United States
  Connect »

Ardelyx Investigative Site 407

San Antonio, TX United States
  Connect »

Ardelyx Investigative Site 401

St. George, UT United States
  Connect »